A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation.
Anti-oxidant activity
Emphysema
Matrix metalloproteinase-9
Neutrophilic airway inflammation
Retinoid X receptor
Vascular endothelial growth factor
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
03 Jan 2019
03 Jan 2019
Historique:
received:
08
08
2018
accepted:
13
12
2018
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
12
3
2019
Statut:
epublish
Résumé
Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate signalling by 9-cis retinoic acid, a vitamin A derivative. RXRs play key roles not only as homodimers but also as heterodimeric partners, e.g., for retinoic acid receptors, vitamin D receptors, and peroxisome proliferator-activated receptors. The NR family may also play important roles in the development of emphysema. However, the role of RXRs in the pathogenesis of emphysema is not well defined. We developed a novel RXR partial agonist (NEt-4IB) and investigated its effect and mechanism compared to a full agonist (bexarotene) in a murine model of emphysema. For emphysema induction, BALB/c mice received intraperitoneal cigarette smoke extract (CSE) or intratracheal porcine pancreas elastase (PPE). Treatment with RXR agonists was initiated before or after emphysema induction. Treatment with NEt-4IB significantly suppressed the increase in static lung compliance and emphysematous changes in CSE-induced emphysema and PPE-induced established and progressive emphysema. NEt-4IB significantly suppressed PPE-induced neutrophilic airway inflammation and the levels of keratinocyte chemoattractant (KC), C-X-C motif ligand5 (CXCL5), interferon (IFN)-γ and IL-17. NEt-4IB also improved the matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and the reduced anti-oxidant activity in bronchoalveolar lavage (BAL) fluid. NEt-4IB suppressed PPE-induced vascular endothelial growth factor (VEGF) expression in the airway. Treatment with NEt-4IB and bexarotene significantly suppressed the increase in static lung compliance and emphysematous changes. However, adverse effects of RXR agonists, including hypertriglyceridemia and hepatomegaly, were observed in bexarotene-treated mice but not in NEt-4IB-treated mice. These data suggest that RXRs play crucial roles in emphysema and airway inflammation, and novel partial RXR agonists could be potential therapeutic strategies for the treatment of PPE- and CSE-induced emphysema.
Sections du résumé
BACKGROUND
BACKGROUND
Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate signalling by 9-cis retinoic acid, a vitamin A derivative. RXRs play key roles not only as homodimers but also as heterodimeric partners, e.g., for retinoic acid receptors, vitamin D receptors, and peroxisome proliferator-activated receptors. The NR family may also play important roles in the development of emphysema. However, the role of RXRs in the pathogenesis of emphysema is not well defined.
METHODS
METHODS
We developed a novel RXR partial agonist (NEt-4IB) and investigated its effect and mechanism compared to a full agonist (bexarotene) in a murine model of emphysema. For emphysema induction, BALB/c mice received intraperitoneal cigarette smoke extract (CSE) or intratracheal porcine pancreas elastase (PPE). Treatment with RXR agonists was initiated before or after emphysema induction.
RESULTS
RESULTS
Treatment with NEt-4IB significantly suppressed the increase in static lung compliance and emphysematous changes in CSE-induced emphysema and PPE-induced established and progressive emphysema. NEt-4IB significantly suppressed PPE-induced neutrophilic airway inflammation and the levels of keratinocyte chemoattractant (KC), C-X-C motif ligand5 (CXCL5), interferon (IFN)-γ and IL-17. NEt-4IB also improved the matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and the reduced anti-oxidant activity in bronchoalveolar lavage (BAL) fluid. NEt-4IB suppressed PPE-induced vascular endothelial growth factor (VEGF) expression in the airway. Treatment with NEt-4IB and bexarotene significantly suppressed the increase in static lung compliance and emphysematous changes. However, adverse effects of RXR agonists, including hypertriglyceridemia and hepatomegaly, were observed in bexarotene-treated mice but not in NEt-4IB-treated mice.
CONCLUSION
CONCLUSIONS
These data suggest that RXRs play crucial roles in emphysema and airway inflammation, and novel partial RXR agonists could be potential therapeutic strategies for the treatment of PPE- and CSE-induced emphysema.
Identifiants
pubmed: 30606200
doi: 10.1186/s12931-018-0963-0
pii: 10.1186/s12931-018-0963-0
pmc: PMC6318915
doi:
Substances chimiques
Retinoid X Receptors
0
Bexarotene
A61RXM4375
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Subventions
Organisme : The Ministry of Education, Science, and Culture of Japan
ID : 2646118906
Organisme : The translational Research Network Program from the Japan Agency for Medical Research and Development, AMED
ID : no number
Références
Proc Natl Acad Sci U S A. 1976 Nov;73(11):3976-8
pubmed: 1069281
Am J Respir Cell Mol Biol. 2000 Aug;23(2):162-7
pubmed: 10919981
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1175-7
pubmed: 10988150
Mol Cell Endocrinol. 2001 Mar 28;174(1-2):71-6
pubmed: 11306173
Arch Dermatol. 2001 May;137(5):581-93
pubmed: 11346336
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 2):S28-38
pubmed: 11734464
Mod Pathol. 2003 Jan;16(1):1-7
pubmed: 12527706
Free Radic Biol Med. 1992 Dec;13(6):659-76
pubmed: 1334034
Thorax. 1964 Sep;19:443-8
pubmed: 14216974
Cell. 2004 Feb 6;116(3):417-29
pubmed: 15016376
Thorax. 2005 Feb;60(2):106-13
pubmed: 15681497
Proc Am Thorac Soc. 2005;2(4):258-66; discussion 290-1
pubmed: 16267346
Respir Res. 2005 Dec 22;6:151
pubmed: 16372907
Br J Cancer. 2006 Mar 13;94(5):654-60
pubmed: 16495926
Am J Respir Crit Care Med. 2006 Jul 15;174(2):161-70
pubmed: 16645174
Chest. 2006 Nov;130(5):1334-45
pubmed: 17099008
Pharmacol Rev. 2006 Dec;58(4):760-72
pubmed: 17132853
Respir Res. 2007 Jul 15;8:53
pubmed: 17631682
Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1149-57
pubmed: 18408070
Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1488-95
pubmed: 19592467
Chest. 2011 May;139(5):1101-1108
pubmed: 20847042
Respir Res. 2010 Sep 29;11:132
pubmed: 20920222
Eur Respir J. 2012 Aug;40(2):306-12
pubmed: 22282548
Biol Pharm Bull. 2012;35(4):629-33
pubmed: 22466572
Eur Respir J. 2013 Jan;41(1):31-8
pubmed: 22523359
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Immunotherapy. 2013 Apr;5(4):427-33
pubmed: 23557425
Am J Respir Cell Mol Biol. 2014 Jan;50(1):18-29
pubmed: 23937413
ACS Chem Neurosci. 2013 Nov 20;4(11):1430-8
pubmed: 24117438
Respir Res. 2013 Oct 12;14:106
pubmed: 24118845
Metab Brain Dis. 2014 Sep;29(3):553-61
pubmed: 24664180
Cell. 2014 Mar 27;157(1):255-66
pubmed: 24679540
J Control Release. 2014 Dec 28;196:154-60
pubmed: 25312542
Int J Chron Obstruct Pulmon Dis. 2014 Oct 17;9:1207-24
pubmed: 25378921
J Med Chem. 2015 Jan 22;58(2):912-26
pubmed: 25486327
PLoS One. 2015 Apr 06;10(4):e0122744
pubmed: 25844636
Int J Chron Obstruct Pulmon Dis. 2015 Apr 07;10:715-24
pubmed: 25897215
Am J Physiol Lung Cell Mol Physiol. 2015 Aug 1;309(3):L293-304
pubmed: 26024894
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Thorax. 2017 Jun;72(6):510-521
pubmed: 28087752
Respir Res. 2017 Jan 23;18(1):23
pubmed: 28114934
Sci Rep. 2017 Jan 24;7:41202
pubmed: 28117425
N Engl J Med. 1995 May 4;332(18):1198-203
pubmed: 7700313
Ann N Y Acad Sci. 1993 May 28;686:12-27; discussion 27-8
pubmed: 8512242
Cell. 1995 Dec 15;83(6):835-9
pubmed: 8521507
Nature. 1997 Mar 27;386(6623):407-10
pubmed: 9121558